Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas

Laboratory Investigation

Volumn 92, Issue 8, 2012, Pages 1181-1190

  Niu, Dong Feng ^a   Kondo, Tetsuo ^a   Nakazawa, Tadao ^a   Oishi, Naoki ^a   Kawasaki, Tomonori ^a   Mochizuki, Kunio ^a   Yamane, Tetsu ^a   Katoh, Ryohei ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

epithelial mesenchymal transition; immunohistochemistry; real time PCR; Runx2; thyroid carcinoma

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANGIOGENIC FACTOR; GELATINASE A; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR TWIST; VASCULOTROPIN A; VASCULOTROPIN C;

ARTICLE; BENIGN TUMOR; CANCER CELL CULTURE; CANCER INVASION; CARCINOMA CELL; CELL ASSAY; CELL INVASION; CELL NUCLEUS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE SILENCING; GOITER; GRAVES DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID ADENOMA; THYROID CARCINOMA; THYROID FOLLICLE CELL; THYROID METASTASIS; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; WESTERN BLOTTING;

EID: 84864428355     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.84     Document Type: Article

References (34)

1. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306.
2. Kondo T, Asa SL, Ezzat S. Epigenetic dysregulation in thyroid neoplasia. Endocrinol Metab Clin North Am 2008;37:389-400.
3. Komori T. Regulation of skeletal development by the Runx family of transcription factors. J Cell Biochem 2005;95:445-453.
4. Maki K, Yamagata T, Mitani K. Role of the RUNX1-EVI1 fusion gene in leukemogenesis. Cancer Sci 2008;99:1878-1883.
5. Kayed H, Jiang X, Keleg S, et al. Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. Br J Cancer 2007;97:1106-1115.
6. Pratap J, Lian JB, Javed A, et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006;25:589-600.
7. Lee YM. Control of RUNX3 by histone methyltransferases. J Cell Biochem 2011;112:394-400.
8. Akech J, Wixted JJ, Bedard K, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010;29:811-821.
9. Sun X, Wei L, Chen Q, et al. HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity. J Biol Chem 2009;284:21881-21890.
10. Papachristou DJ, Papachristou GI, Papaefthimiou OA, et al. The MAPKAP-1/-Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF. Histopathology 2005;47:565-574.
11. Baniwal SK, Khalid O, Gabet Y, et al. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer 2010;9:258.
12. Yuen HF, Kwok WK, Chan KK, et al. TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction. Carcinogenesis 2008;29:1509-1518.
13. Vasko V, Espinosa AV, Scouten W, et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA 2007;104:2803-2808.
14. DeLellis RA, Lloyd RV, Heitz PU, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press: Lyon, France, 2004.
15. Kondo T, Nakazawa T, Murata S, et al. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol 2007;38:1810-1818.
16. Katoh R, Miyagi E, Nakamura N, et al. Expression of thyroid transcription factor-1 (TTF-1) in human C cells and medullary thyroid carcinomas. Hum Pathol 2000;31:386-393.
17. Kondo T, Nakamura N, Suzuki K, et al. Expression of human pendrin in diseased thyroids. J Histochem Cytochem 2003;51:167-173.
18. Ma DF, Kondo T, Nakazawa T, et al. Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. Hum Pathol 2010;41:1550-1557.
19. Chiou WF, Lee CH, Liao JF, et al. 8-Prenylkaempferol accelerates osteoblast maturation through bone morphogenetic protein-2/p38 pathway to activate Runx2 transcription. Life Sci 2011;88:335-342.
20. Blyth K, Vaillant F, Jenkins A, et al. Runx2 in normal tissues and cancer cells: a developing story. Blood Cells Mol Dis 2010;45:117-123.
21. Kondo T, Nakazawa T, Murata SI, et al. Expression of CD73 and its ecto-50-nucleotidase activity are elevated in papillary thyroid carcinomas. Histopathology 2006;48:612-614.
22. Endo T, Kobayashi T. Runx2 deficiency in mice causes decreased thyroglobulin expression and hypothyroidism. Mol Endocrinol 2010;24:1267-1273.
23. Onodera Y, Miki Y, Suzuki T, et al. Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci 2010;101:2670-2675.
24. Chua CW, Chiu YT, Yuen HF, et al. Suppression of androgenindependent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res 2009;15:4322-4335.
25. Nagaraja GM, Othman M, Fox BP, et al. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 2006;25:2328-2338.
26. Lim M, Zhong C, Yang S, et al. Runx2 regulates survivin expression in prostate cancer cells. Lab Invest 2010;90:222-233.
27. Zhang H-Y, Jin L, Stilling GA, et al. RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors. Endocrine 2009;35:101-111.
28. Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med 2008;132:359-372.
29. Pratap J, Javed A, Languino LR, et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005;25:8581-8591.
30. Javed A, Barnes GL, Pratap J, et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 2005;102:1454-1459.
31. Wu Y, Zhou BP. Snail: more than EMT. Cell Adh Migr 2010;4:199-203.
32. Casas E, Kim J, Bendesky A, et al. Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res 2011;71:245-254.
33. Costessi A, Pines A, D'Andrea P, et al. Extracellular nucleotides activate Runx2 in the osteoblast-like HOBIT cell line: a possible molecular link between mechanical stress and osteoblasts' response. Bone 2005;36:418-432.
34. Franceschi RT, Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 2003;88:446-454.